Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity.
Adolescent
Adult
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Child
Child, Preschool
Comorbidity
Coronavirus Infections
/ epidemiology
Female
Health Resources
/ supply & distribution
Humans
Infant
Infant, Newborn
Male
Middle Aged
Models, Statistical
Pandemics
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Young Adult
SARS
public health
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
05
06
2020
revised:
06
08
2020
accepted:
09
08
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
Early reports suggest the fatality rate from COVID-19 varies greatly across countries, but non-random testing and incomplete vital registration systems render it impossible to directly estimate the infection fatality rate (IFR) in many low- and middle-income countries. To fill this gap, we estimate the adjustments required to extrapolate estimates of the IFR from high-income to lower-income regions. Accounting for differences in the distribution of age, sex and relevant comorbidities yields substantial differences in the predicted IFR across 21 world regions, ranging from 0.11% in Western Sub-Saharan Africa to 1.07% for high-income Asia Pacific. However, these predictions must be treated as lower bounds in low- and middle-income countries as they are grounded in fatality rates from countries with advanced health systems. To adjust for health system capacity, we incorporate regional differences in the relative odds of infection fatality from childhood respiratory syncytial virus. This adjustment greatly diminishes but does not entirely erase the demography-based advantage predicted in the lowest income settings, with regional estimates of the predicted COVID-19 IFR ranging from 0.37% in Western Sub-Saharan Africa to 1.45% for Eastern Europe.
Identifiants
pubmed: 32912856
pii: bmjgh-2020-003094
doi: 10.1136/bmjgh-2020-003094
pmc: PMC7482102
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Lancet Glob Health. 2020 Apr;8(4):e497-e510
pubmed: 32087815
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
Lancet. 2010 May 1;375(9725):1500-2
pubmed: 20399494
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451366
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Lancet Infect Dis. 2020 Jun;20(6):630-631
pubmed: 32240633
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664